File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy

TitleCombination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy
Authors
Issue Date2009
PublisherInternational Medical Press. The Journal's web site is located at http://www.intmedpress.com/Journals/AVT/journals_avt_home.cfm
Citation
Antiviral Therapy, 2009, v. 14 n. 5, p. 679-685 How to Cite?
AbstractBackground: This study aimed to identify the baseline hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT) levels and on-treatment HBV DNA levels for favourable outcome in patients receiving 5-year lamivudine. Methods: Virological, serological and biochemical parameters were assessed in 74 hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients at year 5 of therapy. Results: Patients with baseline HBV DNA levels <9 log10 copies/ml and ALT≥-2x the upper limit of normal (ULN) had a significantly higher chance of HBV DNA suppression to <4 log10 copies/ml (76.5%) and HBeAg seroconversion (82.4%), and a lower chance of YMDD mutations (35.3%) compared with patients with HBV DNA<9 log10 copies/ml and ALT<2xULN and patients with HBV DNA≥9 log10 copies/ml (all P<0.05). All patients with these two baseline parameters plus week 4 HBV DNA<4 log10 copies/ml achieved HBV DNA<35 copies/ml, HBeAg seroconversion and ALT normalization without YMDD mutations at year 5. When these two baseline parameters were combined with week 24 HBV DNA<3 log10 copies/ml, 60%, 80% and 90% of patients had HBV DNA<35 copies/ml, <3 log1'0 copies/ml and <4 log10 copies/ml, respectively at year 5. Overall, 90% of patients had HBeAg seroconversion and only 10% had YMDD mutations. Conclusions: For HBeAg-positive patients with baseline HBV DNA<9 log10 copies/ml and ALT≥2xULN, lamivudine could be initiated. For those with HBV DNA<4 log10 copies/ml at week 4 or <3 log10 copies/ml at week 24, continuation of lamivudine treatment would be more likely to result in a good long-term response. © 2009 International Medical Press.
Persistent Identifierhttp://hdl.handle.net/10722/163270
ISSN
2015 Impact Factor: 2.916
2015 SCImago Journal Rankings: 1.361
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorFung, Jen_HK
dc.contributor.authorSeto, WKen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorYuen, JCHen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2012-09-05T05:29:24Z-
dc.date.available2012-09-05T05:29:24Z-
dc.date.issued2009en_HK
dc.identifier.citationAntiviral Therapy, 2009, v. 14 n. 5, p. 679-685en_HK
dc.identifier.issn1359-6535en_HK
dc.identifier.urihttp://hdl.handle.net/10722/163270-
dc.description.abstractBackground: This study aimed to identify the baseline hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT) levels and on-treatment HBV DNA levels for favourable outcome in patients receiving 5-year lamivudine. Methods: Virological, serological and biochemical parameters were assessed in 74 hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients at year 5 of therapy. Results: Patients with baseline HBV DNA levels <9 log10 copies/ml and ALT≥-2x the upper limit of normal (ULN) had a significantly higher chance of HBV DNA suppression to <4 log10 copies/ml (76.5%) and HBeAg seroconversion (82.4%), and a lower chance of YMDD mutations (35.3%) compared with patients with HBV DNA<9 log10 copies/ml and ALT<2xULN and patients with HBV DNA≥9 log10 copies/ml (all P<0.05). All patients with these two baseline parameters plus week 4 HBV DNA<4 log10 copies/ml achieved HBV DNA<35 copies/ml, HBeAg seroconversion and ALT normalization without YMDD mutations at year 5. When these two baseline parameters were combined with week 24 HBV DNA<3 log10 copies/ml, 60%, 80% and 90% of patients had HBV DNA<35 copies/ml, <3 log1'0 copies/ml and <4 log10 copies/ml, respectively at year 5. Overall, 90% of patients had HBeAg seroconversion and only 10% had YMDD mutations. Conclusions: For HBeAg-positive patients with baseline HBV DNA<9 log10 copies/ml and ALT≥2xULN, lamivudine could be initiated. For those with HBV DNA<4 log10 copies/ml at week 4 or <3 log10 copies/ml at week 24, continuation of lamivudine treatment would be more likely to result in a good long-term response. © 2009 International Medical Press.en_HK
dc.languageengen_US
dc.publisherInternational Medical Press. The Journal's web site is located at http://www.intmedpress.com/Journals/AVT/journals_avt_home.cfmen_HK
dc.relation.ispartofAntiviral Therapyen_HK
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAlanine Transaminase - Blooden_US
dc.subject.meshDna, Viral - Blooden_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B E Antigens - Blooden_US
dc.subject.meshHepatitis B Virus - Drug Effects - Geneticsen_US
dc.subject.meshHepatitis B, Chronic - Drug Therapy - Virologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLamivudine - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshReverse Transcriptase Inhibitors - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshViral Loaden_US
dc.subject.meshYoung Adulten_US
dc.titleCombination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapyen_HK
dc.typeArticleen_HK
dc.identifier.emailYuen, MF: mfyuen@hku.hken_HK
dc.identifier.emailFung, J: jfung@sicklehut.comen_HK
dc.identifier.emailSeto, WK: wkseto2@hku.hken_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityFung, J=rp00518en_HK
dc.identifier.authoritySeto, WK=rp01659en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid19704171-
dc.identifier.scopuseid_2-s2.0-69849093757en_HK
dc.identifier.hkuros213677-
dc.identifier.hkuros174348-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-69849093757&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue5en_HK
dc.identifier.spage679en_HK
dc.identifier.epage685en_HK
dc.identifier.isiWOS:000269719200009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridFung, J=23091109300en_HK
dc.identifier.scopusauthoridSeto, WK=23390675900en_HK
dc.identifier.scopusauthoridWong, DKH=7401535819en_HK
dc.identifier.scopusauthoridYuen, JCH=7102620480en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats